ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Alexander I Spira, MD, PhD, FACP

VCS Physicians

Alexander I Spira, MD, PhD, FACP Headshot

Getting a diagnosis of cancer is the most challenging thing any patient and family will have to go through. My job is to provide the most comprehensive options for patients, with state-of-the-art care and compassion.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology and Internal Medicine

Fellowship

Johns Hopkins Hospital, Medical Oncology

Internship

Hospital of the University of Pennsylvania

Residency

Hospital of the University of Pennsylvania

Medical School

New York University School of Medicine

College

Harvard University

Alexander I Spira, MD, PhD, FACP

Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins

Dr. Alexander Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.

As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.

Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.




 

Physician Publications

January 29, 2021

Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer

Read More
January 29, 2021

Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC

Read More
September 1, 2020

Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cance

Read More

More Publications by Alexander I Spira, MD, PhD, FACP

August 11, 2020

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Read More
June 7, 2020

Camidanlumab Tesirine, an Antibody-Drug Conjugate, in Relapsed/Refractory CD25-positive Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia: A Phase I Study

Read More
April 7, 2020

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasThe ANNOUNCE Randomized Clinical Trial

Read More
October 1, 2019

A review of canakinumab and its therapeutic potential for non-small cell lung cancer.

Read More
August 1, 2019

Detection of NRG1 Gene Fusions in Solid Tumors.

Read More
August 1, 2019

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Read More
September 25, 2018

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Read More
March 9, 2016

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Read More
September 14, 2015

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

Read More
June 3, 2013

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Read More
February 1, 2013

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Read More
January 2, 2013

Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma

Read More
June 1, 2012

Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer

Read More
April 16, 2012

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Read More
January 1, 2012

Clinical trial design in the age of molecular profiling.

Read More
September 8, 2011

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Read More
June 1, 2011

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients

Read More
June 1, 2011

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

Read More
June 1, 2011

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Read More
December 4, 2010

Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.

Read More
December 1, 2010

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.

Read More
December 3, 2009

Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations.

Read More
December 1, 2009

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Read More
January 22, 2004

Multidisciplinary Management of Lung Cancer

Read More
January 1, 2002

The use of Chemotherapy in Soft Tissue Sarcomas

Read More

Clinical Trials (106)

Clinical Trial MRG004A-001

"An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors"


Clinical Trial AVB500-PC-005

A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nabpaclitaxel and Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma


Clinical Trial C4401001

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS


Clinical Trial 20291

A Phase 1b/2,  Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects with Advanced Solid Tumors with KRAS G12C Mutation                                         **MANY SUBPROTOCOLS FOR THIS TRIAL**


Clinical Trial 20289

A Phase I Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies


Clinical Trial 20305

An Open-Label, Phase 1b, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Efficacy of the Aryl Hydocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Combination with Pembrolizumab in Participants with Advanced Tumors

All Clinical Trials for Alexander I Spira, MD, PhD, FACP

Clinical Trial MRG004A-001

“An Open-Label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Assess
the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in
Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors”

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04843709

ClinicalTrials.gov Link:

Click Here


Clinical Trial AVB500-PC-005

A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nabpaclitaxel
and Gemcitabine in Patients with Locally Advanced
or Metastatic Pancreatic Adenocarcinoma

Locations:

Fairfax Office

ClinicalTrials.gov ID:

  NCT04983407

ClinicalTrials.gov Link:

Click Here


Clinical Trial C4401001

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE
SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS,
AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED
OR METASTATIC TUMORS

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04881045

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20291

A Phase 1b/2,  Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects with Advanced Solid Tumors with KRAS G12C Mutation                                         **MANY SUBPROTOCOLS FOR THIS TRIAL**

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20289

A Phase I Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04254107

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20305

An Open-Label, Phase 1b, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Efficacy of the Aryl Hydocarbon Receptor Inhibitor (AhRi) BAY 2416964 in Combination with Pembrolizumab in Participants with Advanced Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04999202

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18020

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03400332

ClinicalTrials.gov Link:

Click Here


Clinical Trial TWT-101

A First in Human, Phase 1/2 Study of CFI-402411, Hematopoeitic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advnanced Solid Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04521413

ClinicalTrials.gov Link:

Click Here


Clinical Trial TTX-030-002

A Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04306900

ClinicalTrials.gov Link:

Click Here


Clinical Trial TPX-0022-01

A Phase I, Open-Label, Multicenter, First in Human Study of the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of TPX-0022, A Novel MET/CSF1R/SRC Inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations I MET

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03993873

ClinicalTrials.gov Link:

Click Here


Clinical Trial RTX-24-01

Open-Label, Multicenter, First in Human Phase 1/2 Study of RTX-240 for the Treatment of Patients with Relapsed/Refractory or Locally Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04372706

ClinicalTrials.gov Link:

Click Here


Clinical Trial PEN-866-001

A Phase 1/2a, Open-Label, Mutlicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Patients with Advanced Solidy Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03221400

ClinicalTrials.gov Link:

Click Here


Clinical Trial DF6002-001

A Phase 1/2, First in Human, Multi-Part, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04423029

ClinicalTrials.gov Link:

Click Here


Clinical Trial TPX-0046-01

A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects with Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04161391

ClinicalTrials.gov Link:

Click Here


Clinical Trial ORIC-101-18101

An Open-Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03928314

ClinicalTrials.gov Link:

Click Here


Clinical Trial M19-037

A Phase I, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03893955

ClinicalTrials.gov Link:

Click Here


Clinical Trial NB-ND021 (NM21-1480)-101

Phase 1/2 Study of NM21-1480 (Anti-PD-L1/Anti-4-1BB/Anti-HAS Tri-Specific Antibody) in Adults with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04442126

ClinicalTrials.gov Link:

Click Here


Clinical Trial JAB-3312-1003

A Phase 1/2a, Multi-center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB3312 in Combination with Pembrolizumab or Binimetinib in Adults with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04720976

ClinicalTrials.gov Link:

Click Here


Clinical Trial I-MAB

A Phase I Study of TJ210001 Administered in Subjects with Relapsed or Refractory Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04678921

ClinicalTrials.gov Link:

Click Here


Clinical Trial CPO-100-US-101

A Phase I, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adults with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

  NCT04931823

ClinicalTrials.gov Link:

Click Here


Clinical Trial D967VC00001

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04482309

ClinicalTrials.gov Link:

Click Here


Clinical Trial D976MC00001

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Unresectable and or Mets Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04639219

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20383

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Everolimus in Subjects with Advanced Solid Tumors with KRAS G12C Mutation

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Click Here


Clinical Trial KN 8701

A Phase 1/1b Open-Label, Multicenter, Two-Part Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-8701 in Subjects with BRAF Mutation Positive Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04913285

ClinicalTrials.gov Link:

Click Here


Clinical Trial TCTLR-101

Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04799054

ClinicalTrials.gov Link:

Click Here


Clinical Trial D6185C00001

An Open-Label, Multi-Drug, Biomarker-Directed, Multicenter Phase II Umbrella Study in Patients with NSCLC, Who Progressed on and Anti-PD-1/PD-L1 Containing Therapy

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03334617

ClinicalTrials.gov Link:

Click Here


Clinical Trial D4194C00008

Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III NSCLC on Durvalumab

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04381494

ClinicalTrials.gov Link:

Click Here


Clinical Trial AB154CSP0002

A Phase II Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line NSCLC

ClinicalTrials.gov ID:

NCT04262856

ClinicalTrials.gov Link:

Click Here


Clinical Trial BGB-A317-A1217-302

A Phase III, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination with Tislelizumab Compared to Pembrolizumab in Patients with Previously Untreated, PD-L1 Selected, and Locally Advanced, Unresectable or Metastatic NSCLC


Clinical Trial CC-90011-ST-002

A Phase II, Multicenter, Open-Label, Multicohort Study to Assess Safety and Efficacy of CC-90011 in Combination with Nivolumab in Subjects with Advanced Cancers

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04350463

ClinicalTrials.gov Link:

Click Here


Clinical Trial 17167

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo Versus Placebo as Adjuvant Therapy in Adult Subjects with Stages AJCC/UICC v 8 II-IIIA (T>5cm N2) Completely Resected (R0) NSCLC


Clinical Trial D910MC00001

Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Locations:

Fairfax Office


Clinical Trial 20139

A Phase III, Randomized, Controlled, Multi-Center, 3 Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SOC Chemo Alone for the Treatment of Patients with EGFR Positive, Resectable NSCLC


Clinical Trial D910LC00001

A Phase III, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-Based Chemotherapy in Completely Resected Stage II-III NSCLC


Clinical Trial 21177

A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 in Patients with Solid Tumors Likely to Express NaPi2b

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04396340

ClinicalTrials.gov Link:

Click Here


Clinical Trial ACT16146

Randomized, Open-Label Phase II Study of SAR408701 Combined with Pembrolizumab and Pembrolizumab Alone in Patients with CEACAM5 and PD-L1 Positive Advanced/Metastatic Non-Squamous NSCLC.

ClinicalTrials.gov ID:

NCT04524689

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS8201-A-U206

A Phase 2 Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects with HER2-Mutated Metasatic NSCLC


Clinical Trial 20270

Phase II Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced NSCLC with KRAS G12C Mutation

ClinicalTrials.gov ID:

NCT04613596

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20384

A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG510 (pINN Sotorasib) in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced NSCLC with KRAS G12C Mutation


Clinical Trial U31402-A-U103

A Phase I Open-Label Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Subjects with Locally Advanced or Mets EGFR-Mutated NSCLC

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04676477

ClinicalTrials.gov Link:

Click Here


Clinical Trial 61186372EDI1001

Phase I, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced NSCLC

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02609776

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20250

Phase III, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Paitents with EGFR-Mutated Locally Advanced or Metastatic NSCLC

ClinicalTrials.gov ID:

NCT04487080

ClinicalTrials.gov Link:

Click Here


Clinical Trial TPX-0131-01

Phase I/II Study of TPX-0131, A Novel Oral ALK TKI in Subjects with ALK+ Advanced or Metastatic NSCLC

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04849273

ClinicalTrials.gov Link:

Click Here


Clinical Trial PLX124-04

Phase 1b/2 Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2 Study of PLX2853 in Combination with Olaparib in Subjects with Mets Castration-Resistant Prostate Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04556617

ClinicalTrials.gov Link:

Click Here


Clinical Trial KL 264-01

A Phase I-II, First in Human Study of SKB264 in Patients with Locally Advanced Unresectable and Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04152499

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20414

An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04579757

ClinicalTrials.gov Link:

Click Here


Clinical Trial MRTX849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03785249

ClinicalTrials.gov Link:

Click Here


Clinical Trial PCS6422G1-01

A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

ClinicalTrials.gov ID:

NCT04861987

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20310

A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS G12C

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04185883

ClinicalTrials.gov Link:

Click Here


Clinical Trial 21194

A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib in Combination with MVASI and FOLFIRI and in Combination with MVASI and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS G12C Mutation

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04190135


Clinical Trial RTX-321-01

Phase 1 Trial of RTX-321 for Patients That Are HLA-A+ with Persistent, Recurrent, or Metastatic, Unresectable HPV 16+ Cancers

Locations:

Fairfax Office


Clinical Trial CTMX-2009-002

A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR Positive/HER2 Negative Breast Cancer and of CX2009 as Monotherapy and in Combination with CX-072 for Advanced Triple Negative Breast Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04596150

ClinicalTrials.gov Link:

Click Here


Clinical Trial APG1252SU101

A Multi-Center, Phase I/II Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04210037

ClinicalTrials.gov Link:

Click Here


Clinical Trial U31402-A-U201

A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04619004

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS1062-A-U301

Phase 3 Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04656652

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS1062-A-U202

Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed on or After Kinase Inhibitor Therapy and Platinum Based Chemotherapy

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04484142

ClinicalTrials.gov Link:

Click Here


Clinical Trial D967LC00001

A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04379596

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20344

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04579380

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20381

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)


Clinical Trial 20331

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID:

NCT04620330

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18194

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03748186

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19239

CX-839-014 “KEAPSAKE”: A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04265534

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20249

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

ClinicalTrials.gov ID:

NCT04538664

ClinicalTrials.gov Link:

Click Here


Clinical Trial CLN-081-001

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04036682

ClinicalTrials.gov Link:

Click Here


Clinical Trial ZWI-ZW49-101
Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03821233

ClinicalTrials.gov Link:

Click Here


Clinical Trial PLX124-03

A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04493619

ClinicalTrials.gov Link:

Click Here


Clinical Trial 73841937NSC1001

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04077463

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19211

A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) (D9106C00001)

ClinicalTrials.gov ID:

NCT03800134

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19199

Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) (D5169C00001)

ClinicalTrials.gov ID:

NCT04035486

ClinicalTrials.gov Link:

Click Here


Clinical Trial RTX-240-01

PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY

Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors.

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04372706

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20137

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

ClinicalTrials.gov ID:

NCT04513925

ClinicalTrials.gov Link:

Click Here


Clinical Trial M19-611

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04189614

ClinicalTrials.gov Link:

Click Here


Clinical Trial APG-115-US-002
Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03611868

ClinicalTrials.gov Link:

Click Here


Clinical Trial KL26401

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors who are refractory to Available Standard Therapies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04152499

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19043

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03964727

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19082

A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03454451

ClinicalTrials.gov Link:

Click Here


Clinical Trial TPX-005-001

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

ClinicalTrials.gov ID:

NCT03093116

ClinicalTrials.gov Link:

Click Here


Clinical Trial PSB205

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/ Refractory Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03986606

ClinicalTrials.gov Link:

Click Here


Clinical Trial PLX124-01

A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03297424

ClinicalTrials.gov Link:

Click Here


Clinical Trial ASTX295-01

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03975387

ClinicalTrials.gov Link:

Click Here


Clinical Trial 849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03785249

ClinicalTrials.gov Link:

Click Here


Clinical Trial 14059

Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT3379428


Clinical Trial 101-18101

An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03928314

ClinicalTrials.gov Link:

Click Here


Clinical Trial GO-005

A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03953235

ClinicalTrials.gov Link:

Click Here


Clinical Trial M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03539536

ClinicalTrials.gov Link:

Click Here


Clinical Trial C2321001

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03460977

ClinicalTrials.gov Link:

Click Here


Clinical Trial 1951-CL-0101

A Phase 1 Study of ASP1951 in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03799003

ClinicalTrials.gov Link:

Click Here


Clinical Trial LOXO-RET-17001

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03157128

ClinicalTrials.gov Link:

Click Here


Clinical Trial CP-MGC018-01

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03729596

ClinicalTrials.gov Link:

Click Here


Clinical Trial AO-176-101

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03834948

ClinicalTrials.gov Link:

Click Here


Clinical Trial GO-004

An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03639714

ClinicalTrials.gov Link:

Click Here


Clinical Trial AMXT1501-101A

PHASE I DOSE-FINDING, SAFETY STUDY OF ORAL AMXT 1501 DICAPRATE AND DIFLUOROMETHYLORNITHINE (DFMO) IN PATIENTS WITH ADVANCED SOLID TUMORS

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03536728

ClinicalTrials.gov Link:

Click Here


Clinical Trial Janssen 61186372EDI10051

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02609776

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18033

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)


Clinical Trial GO-003

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer

Locations:

Fairfax Office


Clinical Trial 17-167

A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

ClinicalTrials.gov ID:

NCT03447769

ClinicalTrials.gov Link:

Click Here


Clinical Trial 1948-CL-0101

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03565445

ClinicalTrials.gov Link:

Click Here


Clinical Trial CTMX-M-2029-001

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03543813

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18-020

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03400332

ClinicalTrials.gov Link:

Click Here


Clinical Trial Astex ASTX029

Study of ASTX029 in Subjects With Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03520075

ClinicalTrials.gov Link:

Click Here


Clinical Trial STRO-001-BCM1

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03424603

ClinicalTrials.gov Link:

Click Here


Clinical Trial DS1062-A-J101

First-in-human Study of DS-1062a for Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03401385

ClinicalTrials.gov Link:

Click Here


Clinical Trial Tesaro 4020-01-001

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02817633

ClinicalTrials.gov Link:

Click Here


Clinical Trial R3767-ONC-1613

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03005782

ClinicalTrials.gov Link:

Click Here


Clinical Trial M14-237

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02099058

ClinicalTrials.gov Link:

Click Here


Clinical Trial STARTRK-2

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of patients with locally advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements.

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT02568267

ClinicalTrials.gov Link:

Click Here

Primary Location

Fairfax Office Office

Fairfax Office

Learn More

Other Locations

Awards

February 1, 2020

2020 Northern Virginia Magazine Top Doctors


November 1, 2020

Washington Magazine Top Doctors 2020


January 1, 2020

2020 Virginia Living Top Doctors


November 1, 2019

2019 Washingtonian magazine Top Doctors


January 1, 2019

Northern Virginia Magazine Top Doctor 2019


January 1, 2018

2018 Washingtonian Magazine Top Doctor Nomination


November 1, 2017
Washingtonian Magazne Top Doctors 2017

Washingtonian Magazne Top Doctors 2017


March 9, 2016
Washingtonian Magazine

Washingtonian Top Doctor 2016


September 1, 2015
Washingtonian Magazine

Washingtonian Top Doctor 2015


February 1, 2015
Northern Virginia Magazine

Top Doctor 2015


January 31, 2014
Northern Virginia Magazine

Top Doctor 2014